Coulter Pharmaceutical developed monoclonal antibody-based anti-cancer drugs that hone in on tumor cells without devastating surrounding healthy tissues. The company's flagship product was the first anti-B1 antibody-based therapy for the treatment of non-Hodgkin's lymphoma. The company merged with Corixa in December 2000, which was subsequently acquired by GlaxoSmithKline.